Effect of SARS-CoV-2 vaccination in a vulnerable COVID-19 cohort: a real-life experience in an Italian Hospital
We describe the effect of vaccination on COVID-19-patients admitted at our hospital. Retrospective, single-center study conducted in Genoa, Italy, including patients ≥18years hospitalized for COVID-19 from May to December 2021. Demographical and clinical data were collected, vaccinated (group-A) and not-vaccinated (group-B) patients were compared. Impact of vaccination on mortality, ICU admission, and oxygen need was studied using Cox proportional hazards and logistic regression models after adjusting for propensity scores. Overall, 395 patients SARS-CoV-2 infected were included, of which 150 (38%) were vaccinated and 24...
Source: Journal of Chemotherapy - August 23, 2023 Category: Cancer & Oncology Authors: Chiara Russo Luca Tagliafico Laura Labate Marta Ponzano Michele Mirabella Federica Portunato Carmen Bellezza Sara Mora Eleonora Arboscello Fiammetta Monacelli Alessio Nencioni Alessio Signori Bianca Bruzzone Mauro Giacomini Chiara Dentone Matteo Bassetti Source Type: research
Safety of Sotrovimab use in children with COVID-19: an Italian experience
J Chemother. 2023 Aug 21:1-4. doi: 10.1080/1120009X.2023.2250138. Online ahead of print.ABSTRACTSotrovimab is a monoclonal antibody approved in adult and adolescents at high risk for COVID-19. Thirty-three children evaluated in five Italian paediatric centres received Sotrovimab infusion and were retrospectively enrolled from December 2021 to April 2022. In more than half of cases (19/33, 57.6%) Sotrovimab was prescribed off-label. Overall, the infusion was well tolerated with no significative differences in those receiving an off-label prescription. All children had a complete recovery. Data on the safety of Sotrovimab sh...
Source: Journal of Chemotherapy - August 22, 2023 Category: Cancer & Oncology Authors: Elisabetta Venturini Lara Fusani Andrea Lo Vecchio Sara Maria Scarano Silvia Garazzino Giulia Pruccoli Daniele Don à Laura Lancella Guido Castelli Gattinara Luisa Galli Source Type: research
Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population
J Chemother. 2023 Aug 20:1-11. doi: 10.1080/1120009X.2023.2247208. Online ahead of print.ABSTRACTVoriconazole (VRC) displays highly variable pharmacokinetics impacting treatment efficacy and safety. To provide evidence for optimizing VRC therapy regimens, the authors set out to determine the factors impacting VRC steady-state trough concentration (Cmin) in patients with various albumin (Alb) level. A total of 275 blood samples of 120 patients and their clinical characteristics and genotypes of CYP2C19, CYP3A4, CYP3A5, CYP2C9, FMO3, ABCB1, POR, NR1I2 and NR1I3 were included in this study. Results of multivariate linear regr...
Source: Journal of Chemotherapy - August 21, 2023 Category: Cancer & Oncology Authors: Yuanyuan Li Ying Zhang Jinxia Zhao Jialu Bian Yinyu Zhao Xu Hao Boyu Liu Lei Hu Fang Liu Changqing Yang Yufei Feng Lin Huang Source Type: research
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
J Chemother. 2023 Aug 20:1-9. doi: 10.1080/1120009X.2023.2247207. Online ahead of print.ABSTRACTTo evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were assessed. Pre- and post-NAC TIL levels were determined using biopsy and surgical specimens, respectively. The median TIL rate was significantly different before (17.5%) and after (5%) NAC. Pre- and postoperative Ki-67 index, molecular subtype, pre- and post-NAC TIL concentration, and preoperative residual-canc...
Source: Journal of Chemotherapy - August 21, 2023 Category: Cancer & Oncology Authors: Vedat Bugra Erol Sabin Goktas Aydin Ahmet Bilici Asli Cakir Ozgur Acikgoz Omer Fatih Olmez Pelin Basim Source Type: research
Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and < em > IDH1/2 < /em > mutation: a network meta-analysis
In conclusion, venetoclax plus azacitidine could be a good option for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation. Considering our limits (only trial data-based network meta-analysis et al.), future trials directly comparing these regimens are warranted.PMID:37599456 | DOI:10.1080/1120009X.2023.2247200 (Source: Journal of Chemotherapy)
Source: Journal of Chemotherapy - August 21, 2023 Category: Cancer & Oncology Authors: Lida Wang Jiwu Song Xiangming Xiao Dianfang Li Tianmeng Liu Xiaopo He Source Type: research
